A remyelinating agent remains a distant hope
But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
The pandemic releases its grip on clinical trials
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Philips spends big in-house while Becton favours buying
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Roche and Lilly most vested in research
The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
Covid-19’s clinical damage starts to emerge
170 commercial trials were suspended in March while new patient starts slumped 65% as the pandemic swept the globe. April could look even worse.
Covid-19 forces Lilly to hit the brakes
As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…
Hope replaces hype for coronavirus stocks
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
